GenSpera Inc. – “Why Partner – Part One”

NEW YORK, NY / ACCESSWIRE / July 29, 2015 / GenSpera Inc. (OTCQB: GNSZ) today published a new blog post on The Chairman’s Blog, written by the Company’s chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In part one of a two-part blog post, Dr. Dionne explains GenSpera’s rationale for maximizing shareholder value through strategic partnerships. “In my opinion we have a drug that is effective and of great value, and the advantages of partnering for a company at our stage of development far outweigh the advantages gained by building a fully integrated organization with sales and marketing capabilities,” said Dr. Dionne. Read the full post from Dr. Dionne on TheChairmansBlog.com (http://www.thechairmansblog.com/genspera/craig-dionne/why-partner-part-one/).

About GenSpera

GenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera’s lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com

ReleaseID: 430902